Lyra Therapeutics subleases ~23,704 sq ft lab/office in Waltham, MA

Lyra Therapeutics, Inc.

Sublease with RVAC Medicines for 23,704 sq ft at 880 Winter Street, Waltham, MA.
Term expected to start Jan 1, 2024; expires Nov 30, 2032.
Monthly base rent $150,125.33 (~$1.8M annual); 3% annual escalator; first two months rent-free.
Requires $450,375.99 letter of credit as security deposit; also pays share of operating expenses, utilities, taxes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lyra Therapeutics, Inc. entered into Sublease with RVAC Medicines (US), Inc. valued at $1,801,503.96 (effective 2023-12-21).

Action: entry
Agreement: lease
Counterparty: RVAC Medicines (US), Inc.
Value: $1,801,503.96
Effective: 2023-12-21

Exact text from the filing

On December 21, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a sublease agreement (the “Sublease”) with RVAC Medicines (US), Inc., a Delaware corporation (the “Sublessor”), for approximately 23,704 square feet of laboratory and office space at 880 Winter Street in Waltham, Massachusetts (the “Premises”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-073432

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.